{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "section-411", "type": "clause", "offset": [29, 42]}], "size": 25, "samples": [{"hash": "fYohfufrV5q", "uri": "/contracts/fYohfufrV5q#option-deadline", "label": "Master Collaboration Agreement (Kymera Therapeutics, Inc.)", "score": 31.472278595, "published": true}, {"hash": "gym3iySCjzY", "uri": "/contracts/gym3iySCjzY#option-deadline", "label": "Strategic Collaboration, Option and License Agreement", "score": 30.3408622742, "published": true}, {"hash": "550s9kYTeLb", "uri": "/contracts/550s9kYTeLb#option-deadline", "label": "Strategic Collaboration, Option and License Agreement (CRISPR Therapeutics AG)", "score": 27.7652301788, "published": true}], "snippet": "has the meaning set forth in Section 4.1.1.", "hash": "1c4ef76efa07ae15122fa504c9b6dc0d", "id": 1}, {"snippet_links": [{"key": "set-out", "type": "definition", "offset": [16, 23]}, {"key": "in-clause", "type": "clause", "offset": [24, 33]}], "size": 5, "samples": [{"hash": "bskqJV1LwiI", "uri": "/contracts/bskqJV1LwiI#option-deadline", "label": "Master Services Agreement (Emergent BioSolutions Inc.)", "score": 31.8473644257, "published": true}, {"hash": "aPf6fMfZ2av", "uri": "/contracts/aPf6fMfZ2av#option-deadline", "label": "Master Services Agreement", "score": 31.643825531, "published": true}], "snippet": "has the meaning set out in Clause 1.3.", "hash": "8aa899088ebdc0961ce2c9b9ced10316", "id": 2}, {"snippet_links": [{"key": "standard-option", "type": "clause", "offset": [10, 25]}], "size": 4, "samples": [{"hash": "hkdYULuTDOl", "uri": "/contracts/hkdYULuTDOl#option-deadline", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Isis Pharmaceuticals Inc)", "score": 24.8439426422, "published": true}, {"hash": "9drT7Kf6YHO", "uri": "https://ir.ionispharma.com/static-files/52fd37d3-7f94-4189-acca-d0d9628c9fd6", "label": "ir.ionispharma.com", "score": 9.96235466, "published": false}], "snippet": "means the Standard Option Deadline or ALS Option Deadline, as applicable.", "hash": "789eca8fc61617cb4f90d7b3ead6d557", "id": 3}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "designated-target", "type": "clause", "offset": [25, 42]}, {"key": "subject-to-section", "type": "clause", "offset": [47, 65]}, {"key": "receipt-of", "type": "clause", "offset": [125, 135]}, {"key": "the-effective-date", "type": "clause", "offset": [215, 233]}, {"key": "the-applicable", "type": "clause", "offset": [320, 334]}, {"key": "proposed-target", "type": "definition", "offset": [335, 350]}, {"key": "pursuant-to-section", "type": "definition", "offset": [363, 382]}], "size": 3, "samples": [{"hash": "cwnrEaZTqM2", "uri": "/contracts/cwnrEaZTqM2#option-deadline", "label": "Option and Collaboration Agreement (Denali Therapeutics Inc.)", "score": 29.5284061432, "published": true}, {"hash": "k5x8fWTAhZj", "uri": "/contracts/k5x8fWTAhZj#option-deadline", "label": "Option and Collaboration Agreement (Denali Therapeutics Inc.)", "score": 29.2108154297, "published": true}, {"hash": "hJQ8BscgL7g", "uri": "http://investors.denalitherapeutics.com/static-files/7d466fef-45dc-46bc-b2ef-d5cafecd94da", "label": "Amendment", "score": 14.1704311371, "published": false}], "snippet": "means, with respect to a Designated Target and subject to Section 3.2.3(g), the earlier of (a) [***] days following Takeda\u2019s receipt of [***], or (b) (i) for each Initial Designated Target, the [***] anniversary of the Effective Date or (ii) for any Replacement Designated Target, the [***] anniversary of the date that the applicable Proposed Target was deemed, pursuant to Section 3.1.3, a Replacement Designated Target, as applicable.", "hash": "c998f24a16e39d7ac8c56ccedf5461fc", "id": 4}, {"snippet_links": [{"key": "section-61", "type": "clause", "offset": [29, 40]}], "size": 3, "samples": [{"hash": "5ns9iXDrfxG", "uri": "/contracts/5ns9iXDrfxG#option-deadline", "label": "Factor B Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 30.1608486176, "published": true}], "snippet": "has the meaning set forth in Section 6.1.", "hash": "5fc9ad17e8642035860861b0e6bd9f1b", "id": 5}, {"snippet_links": [{"key": "section-5", "type": "definition", "offset": [29, 38]}, {"key": "this-amendment", "type": "clause", "offset": [42, 56]}], "size": 2, "samples": [{"hash": "dJaLTqb705a", "uri": "/contracts/dJaLTqb705a#option-deadline", "label": "Research, Development and License Agreement (Isis Pharmaceuticals Inc)", "score": 24.1594791412, "published": true}], "snippet": "has the meaning set forth in Section 5 of this Amendment.", "hash": "d35b6074164f60652fa061c501a3c65a", "id": 6}, {"snippet_links": [{"key": "effective-date-of-this-agreement", "type": "clause", "offset": [47, 79]}], "size": 2, "samples": [{"hash": "k5blf85p0Ry", "uri": "/contracts/k5blf85p0Ry#option-deadline", "label": "Research Agreement (Mannkind Corp)", "score": 27.8323059082, "published": true}], "snippet": "means the date that is [\u2026***\u2026] years after the Effective Date of this Agreement.", "hash": "27e278cb39af58e71f531907bc1afb8d", "id": 7}, {"snippet_links": [{"key": "day-of", "type": "clause", "offset": [15, 21]}, {"key": "the-parties-agree", "type": "clause", "offset": [50, 67]}, {"key": "in-writing", "type": "definition", "offset": [68, 78]}, {"key": "to-extend", "type": "clause", "offset": [79, 88]}, {"key": "option-condition", "type": "definition", "offset": [124, 140]}, {"key": "section-32", "type": "clause", "offset": [153, 164]}, {"key": "from-the-effective-date", "type": "clause", "offset": [220, 243]}], "size": 1, "samples": [{"hash": "jQXCpOWjOSL", "uri": "https://masongraphite.com/wp-content/uploads/2022/07/Circular-2022.pdf", "label": "Notice", "score": 15.2477750778, "published": false}], "snippet": "means the last day of the latest periods on which the Parties agree in writing to extend the deadline to satisfy the Second Option Condition pursuant to Section 3.2 of the OJV Agreement and being no later than 36 months from the Effective Date.", "hash": "e5be85a8bcc41c7c220bf385a2b640fb", "id": 8}, {"snippet_links": [{"key": "section-41", "type": "clause", "offset": [29, 40]}, {"key": "certain-information", "type": "clause", "offset": [48, 67]}, {"key": "pursuant-to-regulation-s", "type": "clause", "offset": [103, 127]}, {"key": "excluded-information", "type": "clause", "offset": [153, 173]}, {"key": "not-material", "type": "clause", "offset": [177, 189]}, {"key": "publicly-disclosed", "type": "definition", "offset": [251, 269]}], "size": 1, "samples": [{"hash": "kvuKDdAUp7O", "uri": "/contracts/kvuKDdAUp7O#option-deadline", "label": "Research Collaboration and License Agreement (Dynacure S.A.)", "score": 32.0527038574, "published": true}], "snippet": "has the meaning set forth in Section 4.1. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.", "hash": "e1a61f410094a3e0729938e2cb734601", "id": 9}, {"snippet_links": [{"key": "issuance-of-shares", "type": "clause", "offset": [46, 64]}, {"key": "the-cash-payment", "type": "clause", "offset": [75, 91]}, {"key": "set-out", "type": "definition", "offset": [92, 99]}], "size": 1, "samples": [{"hash": "8IFXYgwEF6l", "uri": "/contracts/8IFXYgwEF6l#option-deadline", "label": "Option Agreement (Foremost Lithium Resources & Technology Ltd.)", "score": 34.0431213379, "published": true}], "snippet": "means each and every date referred to for the issuance of Shares or making the cash payment set out in paragraph 4.2 hereof;", "hash": "1da4f981a32bfb1ece4d72e22b318caa", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYb3B0aW9uLWRlYWRsaW5lIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Option Deadline", "size": 57, "snippet": "has the meaning set forth in Section 4.1.1.", "id": "option-deadline", "examples": ["AstraZeneca will notify Isis whether AstraZeneca is exercising its Option to license the applicable Oncology Target (and all Products included in the applicable Oncology Collaboration Program) by notifying Isis in writing on or before the applicable <strong>Option Deadline</strong>."], "related": [["election-deadline", "Election Deadline", "Election Deadline"], ["completion-deadline", "Completion Deadline", "Completion Deadline"], ["objection-deadline", "Objection Deadline", "Objection Deadline"], ["application-deadline", "Application Deadline", "Application Deadline"], ["plan-objection-deadline", "Plan Objection Deadline", "Plan Objection Deadline"]], "related_snippets": [], "updated": "2025-08-01T04:31:04+00:00"}, "json": true, "cursor": ""}}